Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kinetically guided removal of pegylated liposomal doxorubicin in ovarian cancer
2013-003324-36Phase 4Completed
- Sponsor
- Charles University
- Start
- Sep 2013
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegylated liposomal doxorubicin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Charles University. Primary endpoints: Estimation of individual doxorubicin kinetics and Correlation of kinetic parameters with rheohemapheresis effectiveness and tolerability. Started Sep 2013; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2013-003324-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003324-36.